International trends in erythropoietin use and hemoglobin levels in hemodialysis patients

Kidney International

Volumn 78, Issue 2, 2010, Pages 215-223

  McFarlane, Philip A ^a,d   Pisoni, Ronald L ^b   Eichleay, Margaret A ^b   Wald, Ron ^a,d   Port, Friedrich K ^b   Mendelssohn, David ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

anemia dt (Drug Therapy); erythropoietin ad (Administration Dosage); erythropoietin ec (Economics); health expenditures trends; kidney failure, chronic blood economics therapy; reimbursement mechanisms economics legislation jurisprudence

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH CARE POLICY; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOFILTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; SENSITIVITY ANALYSIS; UNITED STATES;

AGED; DRUG UTILIZATION; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; INTERNATIONALITY; MIDDLE AGED; REIMBURSEMENT MECHANISMS; RENAL DIALYSIS;

EID: 77954243266     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.108     Document Type: Article

References (53)

1. Pisoni RL, Bragg-Gresham JL, Young EW et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111.
2. Steinbrook R. Medicare and erythropoietin. N Engl J Med 2007; 356: 4-6.
3. Steinbrook R. Haemoglobin concentrations in chronic kidney disease. Lancet 2006; 368: 2191-2193.
4. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S11-145.
5. US Food and Drug Administration. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). In: vol.2008 US Food and Drug Administration. Rockville, Maryland, 2007.
6. Pisoni RL, Gillespie BW, Dickinson DM et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 2004; 44: 7-15.
7. Steinwald AB. Testimony Before the Subcommittee on Health, Committee on Ways and Means, House of Representatives. End Stage Renal Disease: Medicare should Pay a Bundled Rate for All ESRD Items and Services (GAO- 07-1050T). In: edited by United States Government Accountability Office United States Government Accountability Office, Washington, DC, 2007.
8. Report to the Chairman, Committee on Ways and Means, House of Representatives. End-Stage Renal Disease: Bundling Medicares Payment for Drugs with Payment for All ESRD Services Would Promote Efficiency and Clinical Flexibility (GAO-07-77). In: edited by United States Government Accountability Office United States Government Accountability Office, Washington, DC, 2006.
9. Dor A, Pauly MV, Eichleay MA et al. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007; 7: 73-111.
10. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 5): 1-50.
11. Will EJ, Cameron JS. European guidelines for renal anaemia-predicting 85% compliance. Nephrol Dial Transplant 2000; 15: 439-440.
12. Maxwell AE. Basic Statistics in Behavioural Research. Penguin Books: England, 1970.
13. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30: S192-S240.
14. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37: S182-S238.
15. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-i47.
16. Barrett BJ, Fenton SS, Ferguson B et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 1999; 10(Suppl 13): S292-S296.
17. Renal Association. Treatment of Adults and Children with Renal Failure: Standards and Audit Measures. In: 3rd edn. Royal College of Physicians of London and the Renal Association: London, 2002.
18. National Collaborating Centre for Chronic Conditions In Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children. Royal College of Physicians: London, 2006.
19. Caring for Australasians with Renal Impairment (CARI). In The CARI Guidelines. Biochemical and Haematological Targets. Westmead: Australia, 2000.
20. Roger S. The CARI guidelines. Haematological targets. Iron. Nephrology (Carlton, Vic) 2006; 11(Suppl 1): S217-S229.
21. Pollock C, McMahon L. The CARI guidelines. Biochemical and haematological targets guidelines. Haemoglobin Nephrol (Carlton, Vic) 2005; 10(Suppl 4): S108-S115.
22. Locatelli F, Pisoni RL, Combe C. et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132. (Pubitemid 38072623)
23. Mendelssohn DC, Yeates KE, Ethier J et al. DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in Canada. Nephrol News Issues 2007; 21: 69-70, 72, 74-166 passim.
24. Rayner H, Greenwood R, MacTier R et al. Estimating the increase in life expectancy of UK haemodialysis patients if clinical practice guidelines for haemodialysis are met. Br J Renal Med 2007; 12: 11-14.
25. Goodkin DA, Bragg-Gresham JL, Koenig KG et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.
26. de Lissovoy G, Powe NR, Griffiths RI et al. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care 1994; 32: 130-140.
27. Young EW, Goodkin DA, Mapes DL et al. The Dialysis Outcomes and Practice Patterns Study (DOPPS): an international hemodialysis study. Kidney Int 2000; 57: S74-S81.
28. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446.
29. Moist LM, Muirhead N, Wazny LD et al. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. Ann Pharmacother 2006; 40: 198-203.
30. Pizzarelli F, David S, Sala P et al. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC). Am J Kidney Dis 2006; 47: 1027-1035.
31. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583.
32. McFarlane PA, Hillmer MP, Dacouris N. A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy. Nephron Clin Pract 2007; 107: c90-c96.
33. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant 2007; 22(Suppl 4): iv19-iv30.
34. Tolman C, Richardson D, Bartlett C et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-1470.
35. Cervelli MJ, Gray N, McDonald S et al. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology (Carlton, Vic) 2005; 10: 129-135.
36. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-118.
37. Nissenson AR. Dosing darbepoetin alfa. Am J Kidney Dis 2002; 40: 872.
38. Bock HA, Hirt-Minkowski P, Brunisholz M et al. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008; 23: 301-308.
39. Aranesp Prescribing Information - version 5. Aranesp Package Insert Prescribing Information for US Health Professionals. In: (vol. 2007) Thousand Oaks, AMGEN, California 2007.
40. Repchinsky C (ed) Compendium of Pharmaceuticals and Specialties (CPS). Canadian Pharmacists Association: Toronto, Canada, 2007.
41. Centers for Medicare and Medicaid Services - Medicare Program. Changes to the hospital outpatient prospective payment system and calendar year 2005 rates; final rule. 42 CFR part 419. Federal Register 2004; 69: 65681-66234.
42. Ashton T, Marshall MR. The organization and financing of dialysis and kidney transplantation services in New Zealand. Int J Health Care Finance Econ 2007; 7: 233-252.
43. Durand-Zaleski I, Combe C, Lang P. International Study of Health Care Organization and Financing for end-stage renal disease in France. Int J Health Care Finance Econ 2007; 7: 171-183.
44. Fukuhara S, Yamazaki C, Hayashino Y et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ 2007; 7: 217-231.
45. Harris A. The organization and funding of the treatment of end-stage renal disease in Australia. Int J Health Care Finance Econ 2007; 7: 113-132.
46. Hirth RA. The organization and financing of kidney dialysis and transplant care in the United States of America. Int J Health Care Finance Econ 2007; 7: 301-318.
47. Kleophas W, Reichel H. International study of health care organization and financing: development of renal replacement therapy in Germany. Int J Health Care Finance Econ 2007; 7: 185-200.
48. Luno J. The organization and financing of end-stage renal disease in Spain. Int J Health Care Finance Econ 2007; 7: 253-267.
49. Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 2007; 7: 149-169.
50. Nicholson T, Roderick P. International Study of Health Care Organization and Financing of renal services in England and Wales. Int J Health Care Finance Econ 2007; 7: 283-299.
51. Pontoriero G, Pozzoni P, Vecchio LD et al. International Study of Health Care Organization and Financing for renal replacement therapy in Italy: an evolving reality. Int J Health Care Finance Econ 2007; 7: 201-215.
52. Van Biesen W, Lameire N, Peeters P et al. Belgiums mixed private/public health care system and its impact on the cost of end-stage renal disease. Int J Health Care Finance Econ 2007; 7: 133-148.
53. Wikstrom B, Fored M, Eichleay MA et al. The financing and organization of medical care for patients with end-stage renal disease in Sweden. Int J Health Care Finance Econ 2007; 7: 269-281.